Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

07:32
12/12/18
12/12
07:32
12/12/18
07:32

Neurocrine says valbenazine did not meet primary endpoint in Phase IIb study

Neurocrine Biosciences announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale in children and adolescents with moderate to severe Tourette syndrome. The types of treatment emergent adverse events observed in this trial were consistent with those seen in other valbenazine studies. "We are very disappointed with the topline data from the T-Force GOLD study given that children and adolescents with Tourette syndrome need better treatment options. This study was well-conducted with a placebo response as expected, but the treatment effect of valbenazine was lower than we had anticipated," said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "We would like to thank the patients, caregivers and investigators for their participation in this study. We will further analyze the data to determine the next steps for valbenazine in Tourette syndrome."

NBIX Neurocrine
$85.72

-0.14 (-0.16%)

11/21/18
ADAM
11/21/18
INITIATION
Target $111
ADAM
Buy
Neurocrine initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated Neurocrine with a Buy rating as he said the company is one of the few where a product launch exceeded expectations. He said he is guardedly optimistic heading into Phase 2b data for Ingrezza in pediatric Tourette syndrome and with the stock's recent pullback, he sees an attractive entry point. He also thinks the pullback could cause investors to look at Neurocrine to be involved in industry consolidation. Kulkarni set a $111 price target on Neurocrine shares.
11/15/18
BARD
11/15/18
NO CHANGE
Target $131
BARD
Outperform
Neurocrine elevated to Fresh Pick, FAERS fears unwarranted, says Baird
Baird analyst Brian Skorney elevated Neurocrine to Fresh Pick and said to take advantage of the unwarranted fear caused by the FDA's FAERS update. The analyst said the update was a regular update to their database and it did yield a numerically higher number of patient deaths. However, he said this is typical because as the number of Ingrezza prescriptions increase, so will the number of incidents. He believes this caused an overreaction and investors should take advantage of the buying opportunity. Skorney reiterated his Outperform rating and $131 price target on Neurocrine shares.
11/15/18
JEFF
11/15/18
NO CHANGE
Target $131
JEFF
Buy
Jefferies says buy Neurocrine after yesterday's 'unwarranted' selloff
Jefferies analyst Biren Amin tells investors to buy shares of Neurocrine Biosciences after hosting a dinner with management. Management shared thoughts on the Ingrezza launch and dispelled recent safety concerns, noting the company rigorously reports the majority of adverse events found in the FDA database and that none of the 88 deaths reported are due to Ingrezza, Amin tells investors in a research note. Further, the analyst thinks the risk/reward on shares into the December Tourettes data is "significant to the upside." Amin views yesterday's selloff as "unwarranted" and keeps a Buy rating on Neurocrine with a $131 price target. The stock closed yesterday down 13%, or $13.37, to $86.13.
11/13/18
LEER
11/13/18
INITIATION
Target $110
LEER
Market Perform
Neurocrine initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Neurocrine with a Market Perform and $110 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Neurocrine, Goodman believes Ingrezza should be a significant product for TD/TS but consensus sales expectations are already high.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$281.31

-2.93 (-1.03%)

, AAPL

Apple

$233.91

-1.35 (-0.57%)

13:00
10/16/19
10/16
13:00
10/16/19
13:00
On The Fly
Fly Intel: What to watch in Netflix earnings report »

Netflix (NFLX) is…

NFLX

Netflix

$281.31

-2.93 (-1.03%)

AAPL

Apple

$233.91

-1.35 (-0.57%)

DIS

Disney

$131.38

1.61 (1.24%)

AMC

AMC Entertainment

$9.28

0.12 (1.31%)

SNE

Sony

$58.66

0.15 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

TSN

Tyson Foods

$82.13

-1.59 (-1.90%)

12:55
10/16/19
10/16
12:55
10/16/19
12:55
Options
Tyson Foods put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

12:55
10/16/19
10/16
12:55
10/16/19
12:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

12:55
10/16/19
10/16
12:55
10/16/19
12:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

NIO

NIO Inc.

$1.48

-0.085 (-5.45%)

12:53
10/16/19
10/16
12:53
10/16/19
12:53
Periodicals
Wuxing government ends investment talks with NIO with no deal, NBD says »

The information office of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:50
10/16/19
10/16
12:50
10/16/19
12:50
General news
NY Fed bought $7.5 B in T-bills in today's purchase »

NY Fed bought $7.5 B in…

JWN

Nordstrom

$34.95

-0.58 (-1.63%)

12:45
10/16/19
10/16
12:45
10/16/19
12:45
Options
Nordstrom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

12:45
10/16/19
10/16
12:45
10/16/19
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

HSIC

Henry Schein

$62.66

0.81 (1.31%)

12:43
10/16/19
10/16
12:43
10/16/19
12:43
Hot Stocks
Henry Schein CEO says 'committed to doing business in an ethical manner' »

Henry Schein issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

FB

Facebook

$189.02

0.21 (0.11%)

, TWTR

Twitter

$39.97

-0.29 (-0.72%)

12:37
10/16/19
10/16
12:37
10/16/19
12:37
On The Fly
#SocialStocks: Facebook still advancing Libra, Twitter clarifies rules »

Welcome to…

FB

Facebook

$189.02

0.21 (0.11%)

TWTR

Twitter

$39.97

-0.29 (-0.72%)

SNAP

Snap

$13.68

-0.41 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 30

    Oct

IRM

Iron Mountain

$32.64

-0.135 (-0.41%)

12:35
10/16/19
10/16
12:35
10/16/19
12:35
Options
Iron Mountain put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 12

    Nov

AMZN

Amazon.com

$1,776.00

7.3 (0.41%)

12:33
10/16/19
10/16
12:33
10/16/19
12:33
Hot Stocks
U.K.'s CMA announces formal investigation of Amazon's Deliveroo investment »

The Competition and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

NBEV

New Age Beverages

$2.73

(0.00%)

12:32
10/16/19
10/16
12:32
10/16/19
12:32
Hot Stocks
New Age Beverages says on Twitter that 'big news coming' for Nestea »

The official Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
10/16/19
10/16
12:30
10/16/19
12:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

NWL

Newell Brands

$19.31

0.14 (0.73%)

12:25
10/16/19
10/16
12:25
10/16/19
12:25
Options
Newell Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.04

0.77 (2.12%)

12:18
10/16/19
10/16
12:18
10/16/19
12:18
Hot Stocks
General Motors confirms UAW's statement regarding proposed tentative agreement »

GM said in a statement:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/16/19
10/16
12:17
10/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
10/16/19
10/16
12:16
10/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$44.40

-3.33 (-6.98%)

12:15
10/16/19
10/16
12:15
10/16/19
12:15
Options
Anaplan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

MCK

McKesson

$146.86

8.69 (6.29%)

, ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

12:11
10/16/19
10/16
12:11
10/16/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks continue in a…

MCK

McKesson

$146.86

8.69 (6.29%)

ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

CAH

Cardinal Health

$49.76

1.83 (3.82%)

JNJ

Johnson & Johnson

$136.44

3.6 (2.71%)

TEVA

Teva

$7.33

0.37 (5.32%)

GM

General Motors

$37.14

0.87 (2.40%)

UAL

United Airlines

$90.00

2.1 (2.39%)

BA

Boeing

$376.35

5.36 (1.44%)

BAC

Bank of America

$30.38

0.64 (2.15%)

MGM

MGM Resorts

$27.47

-0.4 (-1.44%)

BX

Blackstone

$46.86

-0.24 (-0.51%)

ACHN

Achillion

$6.25

2.595 (71.00%)

ALXN

Alexion

$102.60

-2.245 (-2.14%)

SFIX

Stitch Fix

$22.00

1.17 (5.62%)

WDAY

Workday

$158.51

-22.33 (-12.35%)

SNBR

Sleep Number

$45.49

-1.2 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

WB

Weibo

$52.17

2.85 (5.78%)

12:05
10/16/19
10/16
12:05
10/16/19
12:05
Options
Weibo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.00

-0.41 (-7.58%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Aphria falls -8.1% »

Aphria is down -8.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NOW

ServiceNow

$251.40

-23.2 (-8.45%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
ServiceNow falls -8.3% »

ServiceNow is down -8.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

AVD

American Vanguard

$13.39

-1.87 (-12.25%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
American Vanguard falls -12.6% »

American Vanguard is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

HOV

Hovnanian

$28.26

2.2 (8.44%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Hovnanian rises 8.2% »

Hovnanian is up 8.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.